I own shares of BICX and am not trying to rain on anyone's parade. However I really don't think that it's a slam dunk quite yet. If I am not mistaken the meeting with the FDA is a pre-IND meeting. Does anyone know what can be determined at such a meeting? What if the FDA wants a p3 trial to absolutely determine the efficacy of the method of delivery of naletrexone? What if the FDA needs a double blind placebo controled study? What if the FDA wants to see the protocal of such a study?
The compound is approved by the FDA but as far as I can determine the method of delivery is not. If I am not mistaken that is the reason that BICX has difficulty getting insurance companies to pay for the procedure.
News 
Market Data 
Discover 
AI
